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INTRODUCTION 71
The vaccine against hepatitis B virus (HBV) infection is widely regarded as robust, safe and 72 immunogenic (1-3). As such, it is one of the cornerstone strategies through which the 73 international community can work towards the target set by United Nations Sustainable 74 Development Goals (SDGs) for HBV elimination as a public health threat by the year 2030 75 (4,5). In sub-Saharan Africa (sSA), a substantial burden of HBV transmission is likely to occur 76 early in life, either vertically from mother to child, or through horizontal acquisition among 77 young children (6) . In this setting, the HBV vaccine has been progressively rolled out as part 78 of the World Health Organisation (WHO) Expanded Programme on Immunisation (EPI) over 79 the past two decades (6). In many countries, the first dose of vaccine is postponed until age 80 six weeks, when it is given together with other routine immunizations; in South Africa, this is a 81 hexavalent combination (HBV, Diphtheria, Tetanus, Pertussis, Haemophilus influenzae type 82 B, Poliomyelitis) (7) . Populations in sSA are particularly vulnerable to morbidity and mortality 83 due to the high prevalence of HBV infection (≥8% in many regions) (8-10), co-endemic HIV 84 infection (11), poor access to screening and diagnostics, limited deployment of antiviral 85 therapy, stigma of HBV infection, and chronic neglect of education, research and resources 86 (12, 13) . 87
88
Vaccine deployment can be difficult to measure; many children in sSA are born outside 89 healthcare settings, there are no robust data regarding coverage of the three dose regimen 90 (6), and different immunological correlates of protection have been applied (14, 15) . In order 91 to accelerate progress towards elimination goals, a variety of approaches has been 92 suggested, including shifting the first dose to be given at birth (16), additional doses in the 93 context of HIV infection (17, 18) , booster doses in individuals whose antibody titre fails to meet 94 a target threshold (14), and catch-up vaccination campaigns for adolescents and adults. 95
However, there is a lack of robust data to inform which of these measures, individually or in 96 combination, is most effective in shifting populations towards sustained elimination of HBV 97 infection as a public health concern. Given the resource limitations of many settings in which 98 HBV represents a public health challenge, there is an urgent need to underpin interventions 99 with an evidence base derived both from careful observation of the existing impact of 100 vaccination and from projections regarding future outcomes on both the incidence and 101 prevalence of HBV infection. 102
RESULTS 145

Serological evidence of exposure to HBV infection 146
From our cohort of 402 children in Kimberley, South Africa, three were HBsAg-positive (0.7%; 147 Table 1 ). This HBsAg prevalence is significantly lower than in adults in a comparable study 148 population (e.g. 11.1% in a previous study (9); p<0.0001). Exposure to HBV infection was 149 measured using anti-HBc antibody; this was detected in three children (0.7%), one of whom 150 was also HBsAg-positive. The other two were HBsAg negative, indicating previous HBV 151 exposure and clearance. 152 153 We collected written evidence of immunisation from the Road to Health Book (RTHB) in 90.8% 164 HIV-negative (KReC) subjects and 6.3% of HIV positive subjects (total 41.3% of cohort). None 165 of the HBsAg-positive children attended with a written vaccination record (RTHB). Due to 166 missing vaccination records, in the absence of a detectable anti-HBs titre we cannot reliably 167 distinguish between children who are unimmunized, and children who are immunised but fail 168 to mount an antibody response. However, among those with a RTHB record, 81.3% of HIV-169 negative and 100% of HIV-positive children were recorded as having received three HBV 170 vaccine doses. 171 172 Among all children age ≤60 months, 238/310 (77%) had an anti-HBs titre ≥10 mIU/ml 173 suggesting some degree of vaccine-mediated immunity. The median anti-HBs titre in HIV-174 negative children was significantly higher than among the HIV-positive group (196 mIU/ml, vs. 175 11 mIU/ml, respectively, p<0.0001) ( Fig 1A) . There was no detectable anti-HBs antibody in 176 3.4% of HIV-negative vs. 47.8% of HIV-positive children (p<0.0001). Irrespective of the 177 antibody titre used as a threshold for immunity, anti-HBs was higher in HIV-negative compared 178 to HIV-positive children ( Fig 1B) . There was no significant difference in anti-HBs titres between 179 male and female participants, either with or without HIV infection (p=0.49 and 0.31 180 respectively, data not shown). 181 182
Waning of vaccine response with age 183
HIV-positive children with anti-HBs titres ≥100mIU/ml were significantly younger than those 184 with lower antibody titres (median age 17 months vs. 31 months, p=0.0008), while no such 185 difference was observed within the HIV-negative group (Fig 2A) . Using the lower threshold of 186 ≥10mIU/ml, we found no significant difference by age in either the HIV-positive or the HIV-187 negative groups (p=0.17 and 4.48 respectively, data not shown). To expand our view of the 188 HIV-positive group, we also added analysis of an older cohort (92 children aged >60 months), 189 and demonstrated that anti-HBs titres were significantly lower in this older group (p<0.0001), 190 with only 2/92 subjects (2.2%) achieving an anti-HBs titre of ≥10mIU/ml ( Fig 2B) . Anti-HBs 191 titres waned significantly with age up to age 60 months in HIV-positive children ( Fig 2C;  192 p=0.004). We observed a similar trend in the HIV-negative cohort, but this did not reach 193 statistical significance ( Fig 2C; p=0 .07). The proportion of HIV-positive subjects with a 194 detectable anti-HBs titre declined steadily with age in the cohort, contrasting to the trend in 195
HIV-negative subjects, where individuals maintained protective anti-HBs titres despite a trend 196 towards decreasing mean titres ( Fig 2C) . Although the numbers of children in this cohort are 197 small, and we did not collect longitudinal data, these results support previous literature reports 198 that HBV vaccine-mediated immunity wanes over time independently of HIV serostatus, but 199 faster for HIV positive individuals (22, 23) . For HIV-positive children aged ≤60 months, ART treatment data were available for 79% of 204 subjects. Within this group, 71% were receiving ART at the time we tested for anti-HBs, and 205 had received a median of 20 months of treatment (IQR 6-33 months). Comparing anti-HBs 206 titres between ART-treated vs. untreated children, we found no significant difference (p=0.72; 207 76 ART-treated, median anti-HBs 13.3 mIU/ml and 31 untreated children, median anti-HBs 208 14.1 mIU/ml, data not shown). There was also no difference between anti-HBs titres of children 209 treated for ≤12 months vs. >12 months (p=0.50, data not shown). We did not examine the 210 effect of ART on anti-HBs titres in children >60 months due to the low numbers of subjects 211 with a detectable anti-HBs titre (n=2). 212
213
Odds of developing an anti-HBs response 214
We used an odds ratio (OR) analysis to identify factors associated with vaccine-mediated 215 protection ( Fig 2D) . HIV-positive status was associated with lack of protection, for antibody 216 titres of both <10 mIU/ml (OR 26.2, 95% CI 11.2-58.6), and <100 mIU/ml (OR 11.6, 95% CI 217 6.7-20.4). In contrast, younger age (<24 months) was protective, (for anti-HBs <10 mIU/ml OR 218 0.3, 95% CI 0.2-0.5 and for anti-HBs <100 mIU/ml OR 0.3, 95% CI 0.2-0.4). Other 219 characteristics analysed including gender, ART, CD4+ count, CD4+ ratio and HIV viral load 220
were not found to be significantly predictive of anti-HBs titres at either threshold. 221
222
Fitting of a dynamic model to local HBV epidemiology 223
We set out to use our clinical data to inform the development of a dynamic model to provide 224 insights into the long-term outcomes of sustained immunization, and to suggest how 225 prevention strategies can be optimized, for example by enhancement of PMTCT or extended 226 vaccination campaigns targeting older age groups. 227
228
In summary, the model takes into consideration the susceptible proportion of the population 229 (S), the chronic (C) and acute (I) carriers, the immune (R) and the vaccinated (V) ( Fig 3A) . To 230 be able to parameterize HBV or vaccine-related epidemiological traits in age, such as age-231 specific probability of chronicity or decay of vaccine-induced protection, susceptible (S) and 232 vaccinated (V) individuals are divided into three subgroups representing infants (i, <1 years of 233 age), children (c, 1-6 years of age) and older individuals (comprising older children, 234 adolescents and adults, a, >6 years of age). Chronic carriers, C, are divided into HBeAg-positive (C+) and HBeAg-negative (C-) to further allow for different parameterization between 236 these two biologically distinct states. 237
238
Informed by the cohort data described above, natural decay and the effects of HIV sero-status 239 on vaccine-induced protection are also taken into account. We used a Bayesian Markov-chain 240 proportion of HBeAg-negative and HBeAg-positive among chronic carriers ( Fig 3B2) . For 249 parameters for which little or no support was found in the literature (Fig 3C) , the resulting 250 posteriors were well behaved. For parameters using informative priors taken from the literature 251 The posterior for the rate of seroconversion from HBeAg-positive to HBeAg-negative (θ) 255 suggested slow progression, with a median period of ~18.5 years (95% CI [14.3, 21.9]). We 256 note here that although we used an uninformative (uniform) prior for θ, its posterior with 257 median ~5.3% a year, here not accounting directly to age-specificity, is compatible with 258 empirical estimations (24) of yearly rates of less than 2% for <3 years of age and 4-5% for 259 As expected, both HBsAg incidence (Fig 4 A1 ) and HBeAg-positive prevalence (Fig 4 B1 ) 278 reduce faster with increasing neonatal immunization coverage, resulting in shorter times to 279 reach the elimination targets (Fig 4 A2, B2 ). Importantly, even immunization of 100% of 280 neonates is predicted to take ~99 years (95% CI 61 -186) for the HBsAg incidence target to 281 be achieved (Fig 4 A2 ), and ~175 years (95% CI 103 -278) for the HBeAg-positive prevalence 282 target (Fig 4 B2 ). Such long timeframes are supported by a previous modelling study (21) . The model suggests that reaching either of the elimination targets will require different 297 intervention coverage and different time scales. In particular, the target for reducing HBsAg 298 incidence is easier to achieve than reducing HBeAg-prevalence. This implies that for a certain 299 vaccination coverage or PMTCT effort, reductions in HBsAg incidence must be interpreted 300 with caution, as such positive trends will potentially mask the fact that HBeAg-positive 301 prevalence, critical for public health, will not be responding at the same rate. 302 303
Modelling progress towards HBV elimination by the year 2030 based on combinations 304 of neonatal vaccination and PMTCT 305
Based on the premise that interventions in the South African population have been most 306 consistently deployed since roll-out of the HBV vaccine in infancy since 1995 (6), we used our 307 model to determine the impact of combined interventions by the year 2030 ( Fig 5 A1, B1) , and 308 to predict the year at which the 90% reduction in HBsAg incidence and 0.1% HBeAg-positive 309 prevalence targets would be reached ( Fig 5 A2, B2 ). Strikingly, HBsAg incidence could already 310 have been reduced by >90% ( Fig 5 A1 ) if both neonatal vaccination and PMTCT had been 311 deployed at 100% coverage since they became widely available in 1995 (mean predicted year 312 of elimination 2017; Fig 5 A2 ). In reality, complete coverage of such interventions is not 313 possible, and we therefore projected outcomes based on <100% intervention coverage. For 314 example, combining neonatal vaccination and PMTCT with 90% coverage of each since 1995 315 is projected to achieve the HBsAg incidence target by 2028; if this is reduced to 80% coverage 316 then goals will be attained by 2044. To achieve the target reduction in HBeAg-positive 317 prevalence, the projected years are 2072 and 2096 (modelled on 90% coverage and 80% 318 coverage of interventions, respectively, Fig 5 B1, B2 ). Again, these results suggest that setting 319 goals based on HBsAg incidence obfuscates the difficulty of achieving targets based on 320
HBeAg-positive prevalence on similar time scales. 321 322
Projecting the probability of achieving elimination targets based on combinations of 323 neonatal vaccination, PMTCT and enhanced vaccination 324
We simulated the impact of combining neonatal vaccination and PMTCT with additional 325 vaccine deployment in other population groups ( 
Projecting the impact of HIV on the probability of achieving elimination targets
As our clinical cohort is centred in South Africa, at the epicentre of the HIV pandemic, we also 346 used our model to investigate the impact of co-endemic HIV on the success of interventions 347 for HBV. We considered a baseline scenario defined by the epidemiological setting fitted by 348 our model in the context of Kimberley, in which local HIV prevalence was taken into 349 consideration for each of the modelled age groups (Fig 6 B1 , B2, solid line). We then 350 performed a sensitivity exercise, considering alternative scenarios in which HIV prevalence 351 was altered to zero or higher prevalence, projecting HBV interventions into the future. to the time taken to achieve a 50% chance of reaching the goals (Fig 6 B1 ). We also simulated 357 the effect of higher population HIV prevalence (x2, x3 and x4 baseline data for Kimberley) to 358 investigate the potential impact of coinfection in high-risk populations. Increasing HIV 359 prevalence, as expected, has a negative impact on the success of combined interventions for 360
HBV, but the effects are relatively modest. In particular, doubling HIV prevalence would shift 361 the 50% probability endpoint into the future by ~4 years for the HBsAg incidence target, and 362 ~7 years for the HBeAg prevalence target. With increasing HIV prevalence, the negative 363 impact on HBV interventions increases, particularly with respect to reduction in HBeAg 364 prevalence. Encouragingly, as ART is now offered at the point of HIV diagnosis and uptake 365 is consistently increasing, any detrimental impact of HIV coinfection is likely to diminish over 366 time, with more of the HIV-infected population retaining near intact immunity. 367
368
DISCUSSION 369
This is a unique study in which we capitalize on detailed clinical cohort data collected in South 370
Africa, represented here and also in our previous publications (9,30), in order to (i) form a 371 robust view of the dynamics of HBV epidemiology, and (ii) develop a mathematical model of 372 HBV transmission and prevention. Overall, we demonstrate that the optimum population 373 intervention is high coverage neonatal vaccination, and that this can be strengthened by robust 374 deployment of PMTCT. However, we project long time-scales to achieve elimination targets, 375 congruent with the large established reservoir of chronic HBV infection, lack of curative 376 therapy, infection that can persist for the entire life-span of the host, and interventions that 377 target only a small proportion of the population. Developing an evidence-based understanding 378 of the most effective approaches to control and elimination is key in light of the Sustainable 379
Development Goals, and is a particular priority for resource-constrained settings that are often 380 made particularly vulnerable by the high prevalence of both HIV and HBV infection. The 381 outputs from this model could be of direct influence in informing ongoing public health 382 strategies in high-prevalence settings. 383 384
Rationale for combining clinical data and modelling 385
Importantly, by assimilating the results of the clinical cohort and the model, we develop a much 386 more complete picture than either individual approach would provide in isolation. Standing 387 alone, the clinical study could provide false reassurance that vaccination campaigns will be 388 adequate to bring about control or elimination; conversely, in the absence of the cohort, the 389 model could be mistakenly interpreted to suggest that vaccination offers limited benefits to 390 population health in the short-medium term. Only by viewing the two conclusions together can 391 we correctly infer that vaccination is of profound importance in protecting individual children 392 and significantly reducing the burden of infection in paediatric cohorts, but also that continuing 393 to pursue this strategy alone is not sufficient to bring about HBV elimination, or even robust 394 control, within the desired time-scale. Although vaccination is a powerful strategy, it is not the 395 short or medium term route to elimination of this pathogen. 396 397
Comparison with other published models 398
Compared to published models of other vaccine-preventable diseases (31), there is a marked 399 deficit in the existing literature for HBV, with few other modelling efforts represented in the 400 peer-reviewed literature (32,33). Reassuringly, our findings are consistent with those of 401 another recent simulation of HBV prevention (21); we concur in concluding that current 402 vaccine-based interventions will result in a modest reduction in HBV prevalence by the year 403 2030. However, there are also some important differences that distinguish our work from 404 previous efforts: 405 i.
Our evaluation provides the advantages of both clinical data and a mathematical 406 model, with close links between our cohort and simulations, and strengths in 407 interpretation of data derived through different approaches. In so doing, we have also 408 been able to specifically address the impact of co-endemic HIV that has not been 409 factored into previous evaluations, using unique cohort data to implement a data-410 driven approach into the dynamic model. 411
ii.
In contrast to approximating model behaviour to a wide range of epidemiological 412 settings across many geographical regions, we focus on a particular population for 413 which we derive unknown epidemiological parameters and apply a robust data-driven 414 approach to others. Our Bayesian framework therefore stands alone (as a tool) that 415
can be applied to any population for which empirical support of key HBV 416 epidemiological parameters is missing. By supplying the model's code, we can 417 facilitate the use of the tool by other academics. 418
iii.
As outputs, we have used targets for reductions in both HBsAg incidence and HBeAg-419 positive prevalence, and have projected the impact of interventions based specifically 420 on the WHO proposal for 90% vaccination of neonates and 90% PMTCT coverage by 421 2030. Previous studies (20,21) have focused instead on ad hoc control thresholds or 422 impact on the public health problem through reduction of HBV-related deaths. By 423 focusing on two alternative control targets for HBV, we conclude that different 424 intervention efforts and time scales are required to achieve these. Goals based on 425
HBeAg-positive prevalence levels are harder to achieve when compared to reductions 426 in new infections, and reflect important epidemiological and public health traits of 427 chronic infections; our results thus contribute to an ongoing discussion regarding which 428 goals should be set, and their underlying public health implications. 429
430
HBV model projections 431
Although a high coverage of neonatal vaccination combined with robust PMCTC shows 432 potential promise to reach elimination targets, the projected time-frame is currently 433 substantially beyond the 2030 milestone. Furthermore, optimal intervention levels have not 434 been in effect since 1995 and the real time-frame to achieve the goals is therefore expected 435 to be considerably longer. We did not address elimination (extinction) in our projections, but it 436 is clear from our main results that an elimination time-frame is far beyond reach with the 437 interventions currently available, and efforts should, for now, be focused on planning for 438 control of HBV as public health issue rather than elimination of the pathogen. 439
440
The model we have developed is statistically robust based on the parameters we have 441 included for this population, and we believe this is an important parsimonious, data-driven tool, 442 offering the potential to scrutinise different strategies independently from one another. The 443 determinants of an equilibrium in any population depend on a number of factors, which may 444 be determined by characteristics and behaviours of the host population (34) as well as 445 potentially by the genetics of the virus. However, where the relevant epidemiological 446 parameters have been defined, we believe the model could robustly be applied to other 447 settings. 448 449
Impact of HIV on population interventions for HBV 450
Although previous studies in southern Africa have indicated that HBV infection is not 451 significantly associated with HIV status (7,35,36), our data do highlight and corroborate a likely Our results also underscore that a major public health impact is possible even without 485 achieving elimination. Careful adjusting of expectations and aims, according to the scale on 486 which particular changes occur, may inform the setting of realistic targets (e.g. reduction in 487 the prevalence of HBeAg-positive carriers could be the most informative outcome measure). 488
The wrong choice of either target or timescale could result in unnecessary abandonment of a 489 strategy that could have a major impact in a few decades. In addition to informing rational use 490 of interventions that have a positive population impact, our study is also important in cautioning 491 against the use of strategies that may have little or no lasting population impact. This is 492 illustrated by our results for catch-up HBV vaccination, which adds little in situations where 493 high coverage of both neonatal immunization and PMTCT can be attained. Considerable 494 political drive, investing in increased surveillance and reducing barriers to treatment access 495 will also be required in order to accurately monitor progress towards the elimination targets 496 (49). 497 498
Impact of HIV and ART on achieving the 2030 sustainable development goals for HBV 499
Our clinical cohort highlights the day-to-day challenges of drug provision and monitoring within 500 this setting: we did not have access to detailed prospective ART treatment data, guidelines 501 have changed numerous times since 2002, and 3TC was intermittently used as a substitute 502 for nevirapine (NVP) due to supply issues. During the period covered by our study, ART was 503 only introduced in children achieving certain immunological criteria (as per old treatment 504 guidelines), while in future, infected children will be started on treatment as soon as diagnosed, 505 which could restore vaccine responses to similar levels as seen in the HIV-negative 506 population; further studies will be required to assess this over time. ART treatment is relevant 507 We used cohort data to parameterize vaccine-induced protection depending on HIV 516 serostatus and time since vaccination. As far as we know, this is the first data-driven approach 517 to project the effects of HIV prevalence on HBV interventions using a dynamic model. Our 518 projections propose that HIV does have a negative effect on HBV interventions, although HIV 519 prevalence only marginally increases time to reach elimination targets, which may not be 520 significant in light of the long overall time-frames that we project even in the absence of HIV. 521
The high HIV prevalences modelled can occur in specific high-risk groups including sex 522 workers and men who have sex with men (50) and it is likely that increased intervention will 523 be required in these groups to minimise HBV transmission. 524 525
Caveats and limitations 526
Different approaches to recruitment of our HIV-positive and HIV-negative cohorts may have 527 introduced unintentional bias. By using respiratory admissions to hospital for the KReC cohort, 528
we were able to identify and recruit a sufficient number of HIV-negative children, but the KReC 529 children may be less healthy than a comparable group of HIV-negative children in the 530 community, and this approach predominantly selected younger children (on average 9.4 531 months younger than the HIV-positive cohort). 532
533
We set out to focus on children aged <60 months in order to collect data from the RTHB. In 534 practice, we did not capture good RTHB data and data collection from the RTHB is itself 535 subject to bias, as families who attend with such records may be those who are most likely to 536 have immunised their children. Numerous complex social factors are also relevant in 537 determining whether children are immunised; babies born to mothers who have HIV and/or 538 HBV are more likely to be in disadvantaged by poverty, and by illness and death in the family, 539 such that they might be less likely to present for (or respond to) vaccination. However, in this 540 setting (and others where antenatal HBV screening is not routinely deployed (12,51,52)), we 541 deem it unlikely that there is a significant difference in vaccination rates between infants born 542 to HBV-positive versus HBV-negative mothers. Vaccine immunogenicity may be altered by a 543 variety of other factors which we did not measure in this study, including maintenance of cold 544 chain, body site of immunization, vaccine preparation (in this case the monovalent HBV 545 vaccine (Biovac Paed)), circadian timing of vaccine doses, and time of day when samples are 546 collected (53), although existing data for HBV vaccine do not support this (54). 547
548
We relied on HBsAg to detect cases of HBV infection. HBV DNA is a more sensitive screening 549 tool but was not practical due to high cost and lack of availability in this setting. The relatively 550 small numbers in each age group and the lack of longitudinal follow-up for individual children 551 puts limitations on the data showing anti-HBs waning over time, but the trends we observe 552 here are biologically plausible and consistent with the existing literature (23,55). 553
554
We have not considered the influence of population migration on the success of HBV 555 interventions to reach the elimination targets. Migration of non-immune and/or infected 556 individuals into an area would delay the time to achieve the targets estimated by our modelling 557 approach. In the absence of clear data to underpin population migration in southern Africa, we 558 have currently addressed our questions in the assumption that populations are static, but the 559 potential impact on HBV control is an important consideration for regions in which there is 560 significant population flux. 
Study cohorts 599
Recruitment was undertaken in Kimberley, South Africa. A previous study of HBV serology in 600 adults in the same setting found HBsAg prevalence of 9.5% (55/579) (7). Children were 601 recruited as part of the Co-infection in South-African Children (COSAC) study as previously described (30,56). The lower age limit of recruitment was 6 months in order to limit the 603 detection of maternal anti-HBs. 604 605 Children were recruited as follows: 606 1. HIV-negative children age 6-60 months (n=174), recruited through the Kimberley 607
Respiratory Cohort (KReC) as previously described (56). These children were admitted to 608 hospital between July 2014 and August 2016 with a clinical diagnosis of respiratory tract 609 infection. KReC children were confirmed HIV-negative in 163 cases (93.7%). A further 11 610 children did not have an HIV test result recorded, but were assumed to be HIV-negative based 611 on the clinical data recorded at the time of admission to hospital. 612 2. HIV-positive children were recruited primarily from HIV out-patient clinics between 613
September 2009 and July 2016 as previously described (30,56). We recorded date of 614 commencement of anti-retroviral therapy (ART), CD4+ T cell count and percentage, and HIV 615 RNA viral load using the time point closest to the sample that was analysed for HBV serology. 616
For the purpose of analysis, we divided these into two groups according by age: 617 i.
Age 6-60 months; n=136. This group was selected to match the age range of 618 the HIV-negative group, and also included five children who were initially 619 screened for the KReC cohort but tested HIV-positive. 620
Age >60 months (range 64-193 months); n=92. 
Laboratory assessment of HBV status 633
Testing for Hepatitis B serum markers and DNA was performed as previously described; for 634 HIV-positive children this is in keeping with recent implementation of HBV screening in 635
Kimberley (30). Briefly, HBsAg testing was carried out in Kimberley Hospital, South Africa 636 using the Magnetic parcel chemiluminometric immunoassay (MPCI; Advia Centaur platform). 637
Confirmatory HBsAg testing was carried out by the UKAS accredited clinical microbiology 638 laboratory at Oxford University Hospitals (OUH) NHS Foundation Trust, Oxford, UK (Architect 639 i2000). For all samples, anti-HBs and anti-HBc testing were carried out by the OUH laboratory 640 (Architect i2000). Limit of detection of the anti-HBs assay was 10 mIU/ml. 641 642
Threshold for vaccine mediated immunity 643
An absolute threshold for vaccine-mediated immunity is difficult to define, and studies variably 644 quote anti-HBs titres of ≥10 mIU/ml or ≥100 mIU/ml as a correlate of protection. UK 645 recommendations for testing HBV immunity often rely on the more stringent criterion of an 646
anti-HBs titre of ≥100 mIU/ml (14). However, early vaccine studies have highlighted that a titre 647 of ≥10 mIU/ml is likely to be a clinically relevant threshold for protection; a study of children in 648
The Gambia showed that children who attained an anti-HBs titre of ≥10 mIU/ml were most 649 likely to be immune (15), and another study demonstrated increased risk of infection when 650 antibody titres fell <10 mIU/ml (57). Due to the varying use of different thresholds, we have 651 presented our results pertaining to both thresholds of ≥10 mIU/ml and ≥100 mIU/ml. 652 653
Statistical analysis 654
Data from the cohort was analysed using GraphPad Prism v.7.0. We determined significant 655 differences between sub-sets within the cohort using Mann-Whitney U tests for non-656 parametric data, Fisher's exact test for categorical variables and correlation between data 657 points was assessed using Spearman's correlation coefficient. 658 659
Mathematical model of HBV transmission and prevention 660
A mathematical model was developed using ordinary differential equations (ODE) and is 661 We used our mathematical model to simulate the transmission dynamics of HBV and the 667 impact of interventions. Our approach is divided into three steps: fitting of demographic background, fitting of HBV transmission background, and simulation of interventions. The 669 following set of ordinary differential equations (ODE) is used to model the deterministic 670 transmission of HBV under homogeneous mixing. Constant parameters informed by the 671 literature and estimated parameters are described in further detail below. 672
673
We take into consideration the susceptible proportion of the population (Si, Sc, Sa, eq. 1-3), 674
the chronic (C + , C -, eq. 6-7) and acute infections (I, eq. 4), the recovered and immune (R, eq. 675 5) and the vaccinated (Vi, Vc, Va, eq. 8). Susceptible and vaccinated subgroups are divided 676 into 3 main classes representing infants (Si, <1 years of age), children (Sc, 1-6 years of age) 677 and older individuals (Sa, >6 years of age). 678 679
Carriage and infection types 680
Carriers are represented by two chronic infection states depending on HBe-antigen status 681 (designated C + for HBeAg-positive and Cfor HBeAg-negative), and I for acute infection. 682
Individuals may acquire HBV at any of the age classes, developing chronic infection 683 depending on age-associated risks: (1-ψ) for infants, (1-ε) for children, (1-γ) for older ages. 684
We assume that the probability of developing chronic infections decreases with age, with 685 ψ=0.15, ε=0.4, and γ=0.95 (58-60). When developing chronic infection, we assume that all 686 individuals become HBeAg-positive but may lose this status and become HBeAg-negative at 687 a rate θ (61). HBeAg-negative carriers may clear infection spontaneously at a rate ρ, entering 688 the recovered class (R). Acute infections (I) are assumed to last 6 months (62) and are cleared 689 at a rate σ, entering the recovered class (R). 690
Force of Infection 692
All carriers contribute to the force of infection (λ, eq. 11). It is assumed that chronic HBe-693 antigen positive infections (C + ) and acute infections (I) have a higher transmission rate (ββm) 694 than chronic HBe-antigen negative infections (C -) (β) (9): 695 696
Births and Mortality 697
The population is assumed to be of constant size with equal births b (eq. 12) and deaths (µ, 698 µ'). Due to HBV-associated mortality, the lifespan of chronic HBeAg-positive (C + ) individuals 699 is taken to be lower (50 years) than the general lifespan (59 years (11)). In the absence of 700 control, the total number of births (b) is divided into Z (eq. 13), W (eq. 14) and Z' (eq. 17) 701 depending on the probability of vertical transmission (A1, A2) and proportion vaccinated at birth 702 (ωn). W is the proportion of babies born to infected mothers acquiring infection at birth or 703 shortly after, and Z the proportion born susceptible. 704 705
Vertical Transmission 706
Vertical transmission takes place from mothers with chronic infections and is dependent on 707 their HBe-antigen serostatus, with frequency of transmission α1 for HBeAg-positive (C + ) and 708 α2 for HBeAg -(C -). For interventions reducing vertical transmission, α1 and α2 are multiplied by 709
(1-ζ), with ζ Є [0,1] being the impact of the intervention (eq. 15-16). For simplicity and lack of 710 observations for appropriate parameterization, we assume that acute infections do not 711 contribute to vertical transmission. 712 713
Routine vaccination 714
Routine vaccination is implemented under three general strategies: coverage of neonates (Z', 715 eq. 8, 17), coverage of 1-6 years old by vaccinating individuals leaving the susceptible <1 716 years old class (term cωcSi in eq. 9), and coverage of 6+ years old by vaccinating individuals 717 leaving the susceptible 1-6 years old class (term aωaSc in eq. 10). In essence, we model 718 vaccination occurring either at birth, or at particular ages (1 year, 6 years). 719 720
Catch-up vaccination 721
For simplicity, catch-up is modelled in a single event (time step tcu), by moving a proportion of 722 susceptible individuals into the age-corresponding vaccinated classes. In practice, this is an 723 impulse event in the ODE system. Catch-up proportions are age-specific with parameters Ki 724 for <1 years old, Kc for 1-6 years old, and Ka for 6+ years old. 725 726
Markov-chain Monte-Carlo fitting approach 727
In two independent steps, we fit certain ODE model outputs to empirically observed variables 728 in the South African population, to set demographic and transmission backgrounds before background. This is done with the above described fitting approach without transmission (i.e. 753 at t=0, I+C + +C -= 0), using as target variables (Gaussian with standard deviation 1) the 754 
Fitting transmission background 762
After fitting demographic parameters and before considering interventions, we fitted the model 763 to a transmission background. This is done using the above described fitting approach, with 764 fixed aging rates a and c. The target variables are set to the percentage of the population that 765
is HBsAg-positive (total carriers), percentage that are anti-HBc positive (R), and relative 766 prevalences of chronic carriers HBeAg-positive (C + ) and HBeAg-negative (C -) for the 767 population of study. We used target Gaussian distributions (standard deviation 1) with mean 768 30% for anti-HBc, mean 8.3% for total carriers, mean proportion of 73% for HBeAg-negative 769 and 23% for HBeAg-positive (9,66). In this step, the posteriors of the parameters β, ρ, α1, α2, 770 θ and βm are obtained. 771 772
Fitted parameters and priors for transmission setting 773
We fitted six parameters for the local transmission setting (β, ρ, α1, α2, θ and βm). Gaussian 774 informative priors are used for three parameters: frequency of vertical transmission α1 for 775
HBeAg-positive (C + ) with mean M=0.8 and standard deviation SD=0.05, the frequency of 776 vertical transmission α2 for HBeAg -(C -) with M=0.25 and SD=0.05 (59,60,67,68), and the 777 increased transmission factor for chronic HBe-antigen positive infections (C + ) and acute 778 infections (I) βm with M=10 and SD=2.5 (69-72). For β, ρ and θ uninformative, uniform priors 779 are used with ranges of 0 to 30 for β and 0 to 1 for θ and ρ. In the main results we demonstrate 780 that the posteriors for ρ and θ follow the scarce knowledge of these parameters. 781
Simulating deterministic interventions 783
After fitting demographics and transmission backgrounds, when simulating deterministic 784 interventions, we fix a, c, β, ρ, α1, α2, θ and βm to the obtained posterior medians. We vary 785 combinations of the intervention parameters ωn, ωc, ωa, (routine coverage for different ages), Simulations followed the same approach as described for deterministic simulations (see 799 above). However, for each combination of parameters defining the intervention, N=50 800 The WHO target for a 90% reduction in HBsAg incidence, based on the assumption 810 that this applies to chronic infection. (WHO goals also use reductions in HBsAg 811 prevalence, and we have included this approach in Figure Supplements) . 812
An additional target for reduction of HBeAg-positive prevalence to 1 in 1000 (0.1%) in 813 the whole population, relative to the pre-intervention era. 814 815
Fitting of cohort data on HIV serostatus and HBV vaccine-induced protection 816
We started with the assumptions that (i) protection is either constant or decays with age, (ii) 817 vaccine efficacy reported elsewhere for infants is representative of protection levels in the 818 population cohort of 1 year olds (infants), and (iii) HIV status may alter protection levels and 819 decay of vaccine-mediated protection over time (75) . 820 821 First, using a response threshold of ≥100 mIU/ml as a correlate of protection (75), we 822 calculated the percentage of protected individuals in age 1, 2, 3, 4 and 5 years old, as available 823 in the cohort data. Following assumption (i), we normalized the percentage of protected 824 individuals in age by the percentage found for 1 year olds. Following assumption (ii) we 825 olds is seen to be ~95% for HIV-and ~75% for HIV+, as expected. 830
831
We then used nonlinear weighted least-squares to fit the transformed protection cohort series 832 a=0.95246 b=-0.05265 for HIV-negative). As reported elsewhere (75), projection of protection 837 by age showed a significant difference depending on HIV serostatus, both in level of vaccine-838 mediated antibodies, and in decay of protection with age ( Figure Supplement 1C) . 839 840
Modelled HBV vaccine-induced protection in the context of HIV status 841
Given that the age classes in the dynamic model are discrete (<1, 1-6, 6+ years of age) and 842 for simplicity, we parameterized protection according to the predicted (Gaussian) distributions 843 at the mean age of each age class in the model ( Figure Supplement 1D) . That is, we used the 844 predicted mean (M) and standard deviation (SD) at ages 0.5, 3.5, 32,5 years as proxies for 845 protection at model age classes <1, 1-6, 6+ years of age, respectively. The resulting 846 distributions (shown in Figure Supplement with previous studies and pooled ranges reported (75). Note that these values equate to 851 protection at the individual level of each age class, such that, for example, HIV-negative aged 852 <1y with M=0.952 equates to a mean of 95.2% vaccine-induced protection in that age class. 853
Vaccine-induced protection is modelled in the dynamic system using the term (1-∆x) in 855 equations 4 and 7-10, where x relates to a specific age class. The term (1-∆x) therefore models 856 a reduction in risk of infection, with ∆x being the protection offered by the vaccine. Given that 857 vaccine-induced protection is dependent on HIV status, ∆x takes the following forms: 858 859 860 Where Px + is the HIV prevalence at a certain age x, vx + the vaccine-induced protection at a 861 certain age x for HIV-positive individuals, and vxthe vaccine-induced protection at a certain 862 age x for HIV-negative individuals (as determined in the approach detailed above). HIV 863 prevalence levels used in the context of Kimberley were 1% for <1 years of age, 5% for 1-6 864 years of age, and 15% for >6 years of age (based on communications with clinicians in South 865
Africa, (76)). 866 13. 942
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